LGM Pharma Launches Standalone Analytical Services for Drug Developers and Manufacturers
LGM Pharma today announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies.
- LGM Pharma today announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies.
- The company, which already conducts analytical services as part of its integrated contract development and manufacturing (CDMO) activities, now is offering its analytical services expertise and facilities as a standalone contract service for pharmaceutical industry clients.
- We are delighted to be able to offer our first-rate analytical and stability testing services to the broader community of drug manufacturers and developers, said Shailesh Vengurlekar, Senior Vice President, Quality & Regulatory Affairs at LGM Pharma.
- As a result, we now are able to provide a full suite of these services as a standalone option.